Canadian researchers say they have discovered the antibiotic Tequin, made by Bristol-Myers Squibb, carries a higher risk of both low and high blood sugar when compared with other antibiotics. A co-author of the study published in the New England Journal of Medicine said researchers found Tequin users have nearly 17 times the risk of high blood sugar and more than four times the risk of low blood sugar than people who were on other antibiotics.

Related Summaries